Yes, discontinue one of the statins immediately—patients should never be on two statins simultaneously.
You must discontinue either atorvastatin 80mg OR rosuvastatin 40mg, as taking both concurrently provides no additional benefit, significantly increases the risk of serious adverse effects (particularly myopathy and rhabdomyolysis), and is never recommended in any clinical guideline.
Why This is a Critical Error
This prescribing pattern represents a fundamental medication error. All major guidelines 1, 2, 3 define statin therapy by intensity categories (high, moderate, low) and consistently recommend using one statin at the appropriate dose—never combining two statins. The mechanism of action is identical across all statins (HMG-CoA reductase inhibition), so dual therapy offers no pharmacologic advantage while dramatically amplifying toxicity risk.
Immediate Action Required
Select ONE of the following high-intensity statin regimens:
- Rosuvastatin 40mg daily (achieves ~56% LDL-C reduction) 2, 3
- Atorvastatin 80mg daily (achieves ~52% LDL-C reduction) 2, 3
Both are FDA-approved high-intensity options with proven cardiovascular benefit 1, 4, 2.
Which One to Keep?
Rosuvastatin 40mg is the preferred choice based on:
Superior LDL-C lowering efficacy: Rosuvastatin 40mg achieves greater LDL-C reduction (-56%) compared to atorvastatin 80mg (-52%) 5, 6, 7
Better tolerability profile: Rosuvastatin 40mg demonstrates lower rates of adverse drug reactions compared to atorvastatin 80mg (2.91% vs 4.59%), including significantly fewer liver enzyme elevations and muscle symptoms 8
More patients achieve LDL-C targets: 80% of patients on rosuvastatin 40mg reach NCEP ATP III goals versus 72% on atorvastatin 80mg 6
Favorable HDL-C effects: Rosuvastatin produces greater HDL-C increases (+9.6% vs +4.4%) 6
However, atorvastatin 80mg remains an excellent alternative if cost is prohibitive (now generic) or if the patient has prior tolerance established on atorvastatin 9, 10.
Safety Monitoring After Correction
Once you've selected a single statin:
- Baseline labs: Obtain CK, ALT, AST before initiating (if not already done) 11
- Monitor for myopathy: Instruct patient to report unexplained muscle pain, tenderness, weakness, or dark urine immediately 12, 13
- Liver function: Recheck transaminases 1-3 months after starting therapy 14, 15
- Assess for drug interactions: Both statins have significant CYP3A4 interactions—review all concurrent medications 15
If LDL-C Target Still Not Achieved on Monotherapy
If the patient remains above LDL-C goal (<55 mg/dL for very high-risk ASCVD patients) on maximally tolerated statin monotherapy 1, 4:
Add non-statin therapy sequentially:
- Ezetimibe 10mg (adds ~15-20% additional LDL-C reduction) 1, 4
- PCSK9 inhibitor (evolocumab, alirocumab, or inclisiran) if still above goal 1, 4, 16
- Bempedoic acid as alternative if statin-intolerant 4, 16
Common Pitfall to Avoid
Never assume "more is better" with statins. The dose-response curve for LDL-C lowering flattens at higher doses, while adverse effects increase exponentially 15. Combination therapy with different lipid-lowering drug classes (statin + ezetimibe, statin + PCSK9 inhibitor) is evidence-based; combining two statins is not 1, 16.